WHO ICTRP trial
COPD-2VAX: Enhancing Protection Against Respiratory Infections Through…
CTIS2024-519163-18-00 · EU Clinical Trials Information System · Not Recruiting
Key facts
| Trial ID | CTIS2024-519163-18-00 |
|---|---|
| Public title | COPD-2VAX: Enhancing Protection Against Respiratory Infections Through AS01-Mediated Innate Immune Activation in High-Risk Patients |
| Scientific title | COPD-2VAX: Enhancing Protection Against Respiratory Infections Through AS01-Mediated Innate Immune Activation in High-Risk Patients |
| Primary sponsor | Nordsjaellands Hospital |
| Registry | EU Clinical Trials Information System |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): No Therapeutic exploratory (Phase II): No Therapeutic confirmatory - (Phase III): No Therapeutic use - (Phase IV): Yes |
| Countries | Denmark |
| Conditions | Chronic Obstructive Pulmonary Disease (COPD);Therapeutic area: Diseases [C] - Virus Diseases [C02] |
| Interventions | Product Name: Prevenar 20 suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed), Product Code:PRD9493438, Pharmaceutical Form: SUSPENSION FOR INJECTION, Other descriptive name… |
| Registration date | Jan 9, 2025 |
| Target size | 60 |
| Registry page | euclinicaltrials.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: